Advances in molecular therapies in patients with brain tumors

Cancer Control

Volumn 10, Issue 2, 2003, Pages 125-137

  Tremont Lukats, Ivo W ^b   Gilbert, Mark R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; ATRASENTAN; BB 251; BORTEZOMIB; CARBOPLATIN; CELECOXIB; CGP 7978; CILENGITIDE; CISPLATIN; COGS 27023A; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEFITINIB; GEMCITABINE; IMATINIB; LOMUSTINE; LONAFARNIB; MARIMASTAT; PACLITAXEL; PRINOMASTAT; REBIMASTAT; SEMAXANIB; TANOMASTAT; TAXANE DERIVATIVE; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB; VINCRISTINE;

ACNE; ARTHRALGIA; BRAIN TUMOR; CANCER INVASION; CANCER SURVIVAL; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIARRHEA; DOWN REGULATION; DRUG ABSORPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; EDEMA; FATIGUE; GLIOBLASTOMA; GLIOMA; HEADACHE; HUMAN; HYPERTRIGLYCERIDEMIA; LEG EDEMA; LIVER TOXICITY; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; RASH; REVIEW; RHINITIS; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; TUMOR GROWTH; VOMITING;

EID: 0347659463     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480301000204     Document Type: Review

References (170)

1. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002;359:1011-1018.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
3. Holland EC. Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet. 2001;2:120-129.
4. Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev. 2001;15:1311-1333.
5. Tamura M, Gu J, Tran H, et al. PTEN gene and integrin signaling in cancer. J Natl Cancer Inst. 1999;91:1820-1828.
6. Besson A, Yong VW. Mitogenic signaling and the relationship to cell cycle regulation in astrocytomas. J Neurooncol. 2001;51:245-264.
7. Elsayed YA, Sausville EA. Selected novel anticancer treatments targeting cell signaling proteins. Oncologist. 2001;6:517-537.
8. Workman P. Signal transduction pathways: a goldmine for therapeutic targets. In: Sebti SM, Hamilton AD, eds. Farnesyltransferase Inhibitors in Cancer Therapy. Totowa, New Jersey: Humana Press; 2001:1-19.
9. Thiesing JT, Ohno-Jones S, Kolibaba KS, et al. Efficacy of STI571, an ab1 tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-ab1-positive cells. Blood. 2000;96:3195-3199.
10. Traxler P, Bold G, Buchdunger E, et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev. 2001;21:499-512.
11. Mauro MJ, Druker BJ. STI571: targeting BCR-ABL as therapy for CML. Oncologist. 2001;6:233-238.
12. Mauro MJ, O'Dwyer M, Heinrich MC, et al. STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol. 2002;20:325-34.
13. Kilic T, Alberta JA, Zdunek PR, et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. 2000;60:5143-5150.
14. Phase I-II trial of STI571 in patients with recurrent malignant gliomas or meningiomas. Available at: http://www.nabtc.org/PUB-NABTC99-08.htm. Accessed February 12, 2003.
15. Open label phase II study of STI571 administered as daily oral treatment in gliomas. http://www.eortc.be/protoc/details.asp?protocol=16011. Accessed February 12, 2003.
16. Ciardiello F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs. 2000;60:25-32.
17. Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs. 2000;60:15-23.
18. Swaisland H, Laight A, Stafford L, et al. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clin Pharmacokinet. 2001;40:297-306.
19. Tortora G, Ciardiello F. Protein kinase A as target for novel integrated strategies of cancer therapy. Ann NY Acad Sci. 2002;968:139-147.
20. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol. 2002;20:2240-2250.
21. Ranson M, Mansoor W, Jayson G. ZD1839 (Iressa): a selective EGFR-TK inhibitor. Expert Rev Anticancer Ther. 2002;2:161-168.
22. Herbst RS. ZD1839: targeting the epidermal growth factor receptor in cancer therapy. Expert Opin Investig Drugs. 2002;11:837-849.
23. Baselga J, Averbuch SD. ZD1839 ("Iressa") as an anticancer agent. Drugs. 2000;60:33-42.
24. Barker AJ, Gibson KH, Grundy W, et al. Studies leading to the identification of ZD1839 (Iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett. 2001;11:1911-1914.
25. Anderson NG, Ahmad T, Chan K, et al. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer. 2001;94:774-782.
26. Albanell J, Codony-Servat J, Rojo F, et al. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res. 2001;61:6500-6510.
27. Raben D, Helfrich BA, Chan D, et al. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol. 2002;29:37-46.
28. Sirotnak FM, Zakowski MF, Miller VA, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res. 2000;6:4885-4892.
29. Williams KJ, Telfer BA, Strafford IJ, et al. ZD1839 ("Iressa"), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer. 2002;86:1157-1161.
30. Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol. 2002;20:110-124.
31. Gilmore AP, Valentijn AJ, Wang P, et al. Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and trans-activation by insulin-like growth factor receptor. J Biol Chem. 2002;277:27643-2750.
32. Purcell WT, Donehower RC. Evolving therapies: farnesyltransferase inhibitors. Curr Oncol Rep. 2002;4:29-36.
33. Smith JS, Tachibana I, Passe SM, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 2001;93:1246-1256.
34. ZD1839 in treating patients with glioblastoma multiforme in first relapse. Available at: http://www.cancer.gov/clinical_trials/view_clinicaltrials.aspx? version=health+professional&sourceid=16245. Accessed February 12, 2003.
35. Phase II study of ZD1839 in patients with newly diagnosed glioblastoma multiforme. Available at: http://www.cancer.gov/clinical_trials/view_clinicaltrials.aspx? version=health+professional&sourceid=15742. Accessed February 12, 2003.
36. ZD1839 for Treatment of Recurrent or Progressive Malignant Astrocytoma or Glioblastoma and Recurrent or Progressive Meningioma: A Phase II Study With a Phase I Component for Patients Receiving EIAEDs. Available at: http://www.nabtc.org/PUB-NABTC00-01.htm. Accessed February 12, 2003.
37. A Phase I Study of ZD1839 and Temozolomide for the Treatment of Malignant Gliomas. Available at: http://www.nabtc.org/PUB-NABTC01-02.htm. Accessed February 12, 2003.
38. Dy GK, Adjei AA. Novel targets for lung cancer therapy: part I. J Clin Oncol. 2002;20:2881-2894.
39. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2001;19:3267-3279.
40. Norman P. OSI-774 OSI pharmaceuticals. Curr Opin Investig Drugs. 2001;2:298-304.
41. Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem. 2002;277:46265-46272.
42. Prados M. A phase I study of OSI-774 + temozolomide in patients for recurrent or stable malignant glioma. Houston, Texas. (Personal communication, 2002.)
43. Brunn GJ, Williams J, Sabers C, et al. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 1996;15:5256-5267.
44. Dudkin L, Dilling MB, Cheshire PJ, et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res. 2001;7:1758-1764.
45. Garber K. Rapamycin's resurrection: a new way to target the cancer cell cycle. J Natl Cancer Inst. 2001;93:1517-1519.
46. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene. 2000;19:6680-6686.
47. Alexandre J, Raymond E, Armand JP. Rapamycin and CCI-779 [in French]. Bull Cancer. 1999;86:808-811.
48. Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs. 2002;3:295-304.
49. Owa T, Yoshino H, Yoshimatsu K, et al. Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. Curr Med Chem. 2001;8:1487-1503.
50. Shi Y, Hsu JH, Hu L, et al. Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6. J Biol Chem. 2002;277:15712-15720.
51. Yu K, Toral-Barza L, Discafani C, et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer. 2001;8:249-258.
52. Geoerger B, Kerr K, Tang CB, et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res. 2001;61:1527-1532.
53. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA. 2001;98:10314-10319.
54. Podsypanina K, Lee RT, Politis C, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci USA. 2001;98:10320-10325.
55. Sarkaria JN, Carlson BL, Mladek AC, et al. Rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Neuro-oncol. 2002;4:359.
56. Phase I/II Trial of CCI-779 in Patients with Malignant Glioma. Available at: http://www.nabtc.org/PUB-NABTCO1-01.htm. Accessed February 12, 2003.
57. Chang S, Wen PY, Greenberg H, et al. Phase I study of CCI-779 in patients with recurrent malignant glioma (MG) on enzyme inducing antiepileptic drugs (EIAEDs). Neuro-oncol. 2002;4:367.
58. A Phase II Study of CCI-779 in Patients With Recurrent Glioblastoma Multiforme. Available at: http://ncctg.mayo.edu/protocols/N997B. Accessed February 12, 2003.
59. Buckner JC, Prados M, Rowinsky EK, et al. A phase I study of the safety, tolerability, and pharmacokinetics of intravenous CCI-779 given once daily for 5 days every two weeks to patients with CNS tumors. Neuro-oncol. 2002;4:365.
60. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation. 1997;64:36-42.
61. Schuurman HJ, Cottens S, Fuchs S, et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation. 1997;64:32-35.
62. Sedrani R, Cottens S, Kallen J, et al. Chemical modification of rapamycin: the discovery of SDZ RAD. Transplant Proc. 1998;30:2192-2194.
63. Haubitz M, Brunkhorst R. Influence of a novel rapamycin analog SDZ RAD on endothelial tissue factor and adhesion molecule expression. Transplant Proc. 2002;34:1124-1126.
64. SDZ RAD. Rapamycin SDZ. Drugs R D. 1999;1:97-99.
65. Karp JE, Kaufmann SH, Adjei AA, et al. Current status of clinical trials of farnesyltransferase inhibitors. Curr Opin Oncol. 2001;13:470-476.
66. Patnaik A, Rowinsky EK. Early clinical experience with farnesyl protein transferase inhibitors. In: Sebti SM, Hamilton AD, eds. Farnesyltransferase Inhibitors in Cancer Therapy. Totowa, New Jersey: Humana Press; 2000:233-249.
67. Tamanoi F, Kato-Stankiewicz J, Jiang C, et al. Farnesylated proteins and cell cycle progression. J Cell Biochem Suppl. 2001;37:64-70.
68. Glass TL, Liu TJ, Yung WK. Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336. Neuro-oncol. 2000;2:151-158.
69. Shi B, Yaremko B, Hajian G, et al. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother Pharmacol. 2000;46:387-393.
70. Hoover RR, Mahon FX, Melo JV, et al. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood. 2002;100:1068-1071.
71. Adjei AA, Davis JN, Bruzek LM, et al. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin Cancer Res. 2001;7:1438-1445.
72. Wang H, Maurer BJ, Reynolds CP, et al. N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase. Cancer Res. 2001;61:5102-5105.
73. Phase II evaluation of temozolomide and farnesyl transferase inhibitor (SCH66336) for the treatment of recurrent and progressive glioblastoma multiforme. Available at: http://utm-notes-db2.mdacc.tmc.edu/mdacc/ClinicalTrialsWP.nsf/Index/DM01-258. Accessed February 12, 2003.
74. Delmas C, Heliez C, Cohen-Jonathan E, et al. Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation. Int J Cancer. 2002;100:43-48.
75. Zujewski J, Horak ID, Bol CJ, et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol. 2000;18:927-941.
76. Crul M, de Klerk GJ, Swart M, et al. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol. 2002;20:2726-2735.
77. A Phase I and II Trial of R115777 in Patients with Recurrent Malignant Gliomas. Available at: http://www.nabtc.org/PUB-NABTC99-01.htm. Accessed February 12, 2003.
78. Cloughesy TF, Kuhn J, Wen P, et al. Phase II trial of R115777 (Zarnestra) in patients with recurrent glioma not taking enzyme inducing antiepileptic drugs (EIAED): a North American Brain Tumor Consortium (NABTC) report. Proc Annu Meet Am Soc Clin Oncol. 2002;21:317. Abstract.
79. Rosen LS. Angiogenesis inhibition in solid tumors. Cancer J. 2001;7:S120-S128.
80. Vajkoczy P, Menger MD, Vollmar B, et al. Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia. 1999;1:31-41.
81. Shepherd FA. Angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer. 2001;34:S81-S89.
82. Shaheen RM, Davis DW, Liu W, et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res. 1999;59:5412-5416.
83. Mendel DB, Schreck RE, West DC, et al. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin Cancer Res. 2000;6:4848-4858.
84. Mendel DB, Laird AD, Smolich BD, et al. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des. 2000;15:29-41.
85. A Phase I and II Trial of SU5416 in Patients with Recurrent High Grade Astrocytomas or Mixed Gliomas. Available at: http://www.nabtc.org/PUB-NABTC99-02.htm. Accessed February 12, 2003.
86. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000;60:2178-2189.
87. Drevs J, Hofmann I, Hugenschmidt H, et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res. 2000;60:4819-4824.
88. Bold G, Altmann KH, Frei J, et al. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J Med Chem. 2000;43:2310-2323.
89. Hess C, Vuong V, Hegyi I, et al. Effect of VEGF receptor inhibitor PTK787/ZK222584 combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer. 2001;85:2010-2016.
90. A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous once daily dosing schedule in patients with glioblastoma multiforme. Available at: http://utm-notes-db2.mdacc.tmc.edu/mdacc/ClinicalTrialsWP.nsf/Index/ID98-317. Accessed February 12, 2003.
91. A phase IB, open-label, 2-arm dose-escalation study of PTK787/ZK 222584 in combination with single agent chemotherapy, either temozolomide (arm 1) or lomustine (arm 2) in patients with glioblastoma multiforme (GBM). Available at: http://utm-notes-db2.mdacc.tmc.edu/mdacc/ClinicalTrialsWP.nsf/Index/DM01-401. Accessed February 12, 2003.
92. Yung WK, Friedman H, Jackson E, et al. A phase I trial of PTK787/ZK 222584 (PTK/ZK), a novel oral VEGFR TK inhibitor in recurrent glioblastoma. Proc Annu Meet Am Soc Clin Oncol. 2002;21:315. Abstract.
93. Reardon DA, Friedman H, Yung WK, et al. A phase I trial of temodar plus PTK787/ZK222584 (PTK/ZK), a novel oral VEGFR TK inhibitor, for patients with recurrent glioblastoma. Neuro-oncol. 2002;4:375.
94. Webb CP, Vande Woude GF. Genes that regulate metastasis and angiogenesis. J Neurooncol. 2000;50:71-87.
95. Wary KK, Mainiero F, Isakoff SJ, et al. The adaptor protein Shc couples a class of integrins to the control of cell cycle progression. Cell. 1996;87:733-743.
96. Wary KK, Dans M, Mariotti A, et al. Biochemical analysis of integrin-mediated Shc signaling. Methods Mol Biol. 1999;129:35-49.
97. Oktay M, Wary KK, Dans M, et al. Integrin-mediated activation of focal adhesion kinase is required for signaling to Jun NH2-terminal kinase and progression through the G1 phase of the cell cycle. J Cell Biol. 1999;145:1461-1469.
98. Barberis L, Wary KK, Fiucci G, et al. Distinct roles of the adaptor protein Shc and focal adhesion kinase in integrin signaling to ERK J. Biol Chem. 2000;275:36532-36540.
99. Mettouchi A, Klein S, Guo W, et al. Integrin-specific activation of Rac controls progression through the G(1) phase of the cell cycle. Mol Cell. 2001;8:115-127.
100. Erdreich-Epstein A, Shimada H, Groshen S, et al. Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res. 2000;60:712-721.
101. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91:4082-4085.
102. Calabrese L, Fleischer AB. Thalidomide: current and potential clinical applications. Am J Med. 2000;108:487-495.
103. Cohen MH. Thalidomide in the treatment of high-grade gliomas. J Clin Oncol. 2000;18:3453.
104. Adlard JW. Thalidomide in the treatment of cancer. Anti-cancer Drugs. 2000;11:787-791.
105. Kirsch M, Schackert G, Black PM. Anti-angiogenic treatment strategies for malignant brain tumors. J Neurooncol. 2000;50:149-163.
106. Nieder C, Nestle U. A review of current and future treatment strategies for malignant astrocytomas in adults. Strahlenther Onkol. 2000;176:251-258.
107. Eriksson T, Bjorkman S, Hoglund P. Clinical pharmacology of thalidomide. Eur J Clin Pharmacol. 2001;57:365-376.
108. Amato RJ. Thalidomide: an antineoplastic agent. Curr Oncol Rep. 2002;4:56-62.
109. Meierhofer C, Dunzendorfer S, Wiedermann CJ. Theoretical basis for the activity of thalidomide. BioDrugs. 2001;15:681-703.
110. Zhou S, Kestell P, Tingle MD, et al. Thalidomide in cancer treatment: a potential role in the elderly? Drugs Aging. 2002;19:85-100.
111. Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol. 2000;18:708-715.
112. Marx GM, Pavlakis N, McCowatt S, et al. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J Neurooncol. 2001;54:31-38.
113. Short SC, Traish D, Dowe A, et al. Thalidomide as an anti-angiogenic agent in relapsed gliomas. J Neurooncol. 2001;51:41-45.
114. Groves MD, Tremont-Lukats IW, Conrad C, et al. A phase II trial of temozolomide plus thalidomide (NABTC 99-04) for recurrent glioblastoma multiforme. Neuro-Oncol. 2002;4:S41.
115. Hwu WJ, Krown SE, Panageas KS, et al. Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. J Clin Oncol. 2002;20:2610-2615.
116. Kamm W, Jonczyk A, Jung T, et al. Evaluation of absorption enhancement for a potent cyclopeptidic alpha(nu)beta(3)-antagonist in a human intestinal cell line (Caco-2). Eur J Pharm Sci. 2000;10:205-214.
117. MacDonald TJ, Taga T, Shimada H, et al. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery. 2001;48:151-157.
118. Herbst RS, Hidalgo M, Pierson AS, et al. Angiogenesis inhibitors in clinical development for lung cancer. Semin Oncol. 2002;29:66-77.
119. Taga T, Suzuki A, Gonzalez-Gomez I, et al. alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer. 2002;98:690-697.
120. Phase I/II study of EMD 121974 in patients with progressive or recurrent malignant glioma. Available at: http://www.cancer.gov/clinical_trials/view_clinicaltrials.aspx? version=health+professional& args=38;e270366a-5ea0-4bfb-801a-37c51e39509b. Accessed February 12, 2003.
121. Nabors LB, Rosenfeld SS, Mikkelsen T, et al. A phase I trial of EMD 121974 for treatment of patients with recurrent malignant gliomas. Neuro-oncol. 2002;4:373.
122. Egidy G, Eberl LP, Valdenaire O, et al. The endothelin system in human glioblastoma. Lab Invest. 2000;80:1681-1689.
123. Wessale JL, Adler AL, Novosad EI, et al. Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: ex vivo and in vivo studies. Clin Sci (Lond). 2002;103:112S-117S.
124. Samara E, Dutta S, Cao G, et al. Single-dose pharmacokinetics of atrasentan, an endothelin-A receptor antagonist. J Clin Pharmacol. 2001;41:397403.
125. Gosselin M, Goulet S, Wu-Wong JR, et al. Effects of a selective ET(A)-receptor antagonist, atrasentan (ABT-627), in murine models of allergic asthma: demonstration of mouse strain specificity. Clin Sci (Lond). 2002;103:367S-70S.
126. Carducci MA, Nelson JB, Bowling MK, et al. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J Clin Oncol. 2002;20:2171-2180.
127. Asano T, Aoyagi M, Hirakawa K, et al. Effect of endothelin-1 as growth factor on a human glioma cell line; its characteristic promotion of DNA synthesis. J Neurooncol. 1994;18:1-7.
128. Kawanabe Y, Hashimoto N, Masaki T. Effects of extracellular Ca2+ influx on endothelin-1-induced intracellular mitogenic cascades in C6 glioma cells. Eur J Pharmacol. 2002;435:119-123.
129. Stiles JD, Ostrow PT, Balos LL, et al. Correlation of endothelin-1 and transforming growth factor beta 1 with malignancy and vascularity in human gliomas. J Neuropathol Exp Neurol. 1997;56:435-439.
130. Atrasentan prolongs time to progression in prostate cancer patients. Oncology (Huntingt). 2001;15:833-917.
131. Atrasentan demonstrates survival benefit in hormone-refractory prostate cancer. Expert Rev Anticancer Ther. 2002;2:245.
132. Zhang W, Sakai N, Yamada H, et al. Endothelin-1 induces intracellular calcium rise and inositol 1,4,5-trisphosphate formation in cultured rat and human glioma cells. Neurosci Lett. 1990;112:199-204.
133. Zhang W, Sakai N, Fu T, et al. Diacylglycerol formation and DNA synthesis in endothelin-stimulated rat C6 glioma cells: the possible role of phosphatidylcholine breakdown. Neurosci Lett. 1991;123:164-166.
134. Couraud PO, Durieu-Trautmann O, Nguyen DL, et al. Functional endothelin-1 receptors in rat astrocytoma C6. Eur J Pharmacol. 1991;206:191-198.
135. Jae HS, Winn M, von Geldern TW, et al. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 5. Highly selective, potent, and orally active ET(A) antagonists. J Med Chem. 2001;44:3978-3984.
136. Phase I study of Atrasentan in patients with progressive or recurrent malignant glioma. Available at: http://www.cancer.gov/clinical_trials/view_clinicaltrials.aspx? version=health+professional& args=5;d36861ad-86a2-424a-8162-2fa94b484597. Accessed February 12, 2003.
137. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 2001;93:178-193.
138. Denis LJ, Verweij J. Matrix metalloproteinase inhibitors: present achievements and future prospects. Invest New Drugs. 1997;15:175-185.
139. Drummond AH, Beckett P, Brown PD, et al. Preclinical and clinical studies of MMP inhibitors in cancer. Ann N Y Acad Sci. 1999;878:228-235.
140. Heath EI, Grochow LB. Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs. 2000;59:1043-55.
141. Millar AW, Brown PD, Moore J, et al. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br J Clin Pharmacol. 1998;45:21-26.
142. Rasmussen HS, McCann PP. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther. 1997;75:69-75.
143. Groves MD, Puduvalli VK, Hess KR, et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol. 2002;20:1383-1388.
144. Groves MD, Puduvalli VK, Gilbert MR, et al. A phase II study of temozolomide plus marimastat for recurrent anaplastic glioma (AG). Neuro-oncol. 2002;4:S369.
145. New P, Mikkelsen T, Phuphanich S, et al. A phase I/II study of COL-3 administered on a continuous oral schedule in patients with recurrent high grade glioma. Preliminary results of the NABTT 9809 clinical trial. Neuro-oncol. 2002;4:373.
146. Price A, Shi Q, Morris D, et al. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin Cancer Res. 1999;5:845-854.
147. Brown PD. Ongoing trials with matrix metalloproteinase inhibitors. Expert Opin Investig Drugs. 2000;9:2167-2177.
148. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene. 2000;19:6642-6650.
149. Scatena R. Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor: a novel pharmacological approach for tissue remodeling-related diseases. Expert Opin Investig Drugs. 2000;9:2159-2165.
150. Levine PA, Phuphanich S, Glantz MJ, et al. Randomized phase II study of temozolomide (TMZ) with and without the metalloprotease (MMP) inhibitor prinomastat in patients (pts) with glioblastoma multiforme (GBM) following best surgery and radiation therapy. Proc Annu Meet Am Soc Clin Oncol. 2002;21:100. Abstract.
151. Adams J. Proteasome inhibition in cancer: development of PS-341. Semin Oncol. 2001;28:613-619.
152. Adams J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol Med. 2002;8:S49-S54.
153. Adams J. Development of the proteasome inhibitor PS-341. Oncologist. 2002;7:9-16.
154. Pervan M, Pajonk F, Sun JR, et al. Molecular pathways that modify tumor radiation response. Am J Clin Oncol. 2001;24:481-485.
155. Teicher BA, Ara G, Herbst R, et al. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res. 1999;5:2638-2645.
156. Ling YH, Liebes L, Ng B, et al. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther. 2002;1:841-849.
157. Phase I study of PS-341 in patients with recurrent glioma. Available at: http://www.cancer.gov/clinicaltrials/view_clinicaltrials.aspx? version=healthprofessional&cdrid=68326. Accessed February 12, 2003.
158. Ishizaki Y, Morita I, Murota S. Arachidonic acid metabolism in cultured astrocytes from rat embryo and in C6 glioma cells. Brain Res. 1989;494:138-142.
159. Blomgren H, Kling-Andersson G. Growth inhibition of human malignant glioma cells in vitro by agents which interfere with biosynthesis of eicosanoids. Anticancer Res. 1992;12:981-986.
160. Kurzel F, Hagel C, Zapf S, et al. Cyclo-oxygenase inhibitors and thromboxane synthase inhibitors differentially regulate migration arrest, growth inhibition and apoptosis in human glioma cells. Acta Neurocbir (Wien). 2002;144:71-87.
161. Gáti I, Bergstrom M, Westerberg G, et al. Effects of prostaglandin and leukotriene inhibitors on the growth of human glioma spheroids. Eur J Cancer. 1990;26:802-807.
162. Gáti I, Bergstrom M, Csoka K, et al. Effects of the 5-lipoxygenase inhibitors AA-863 and U-60,257 on human glioma cell lines. Prostaglandins Leukot Essent Fatty Acids. 1990;40:117-124.
163. Portnow J, Suleman S, Grossman SA, et al. A cyclooxygenase-2 (COX-2) inhibitor compared with dexamethasone in a survival study of rats with intracerebral 9L gliosarcomas. Neuro-oncol. 2002;4:22-25.
164. King JG Jr, Khalili K. Inhibition of human brain tumor cell growth by the anti-inflammatory drug, flurbiprofen. Oncogene. 2001;20:6864-6870.
165. Ristimaki A, Honkanen N, Jankala H, et al. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997;57:1276-1280.
166. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107:1183-1188.
167. Shono T, Tofilon PJ, Bruner JM, et al. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res. 2001;61:4375-4381.
168. Joki T, Heese O, Nikas DC, et al. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res. 2000;60:4926-4931.
169. A phase II trial of isotretinoin and celecoxib for recurrent glioblastoma multiforme. Available at: http://utm-notes-db2.mdacc.tmc.edu/mdacc/ClinicalTrialsWP.nsf/Index/ID02-306. Accessed February 12, 2003.
170. Lang FF, Gilbert MR, Puduvalli VK, et al. Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies. Neuro-oncol. 2002;4:268-277.